ArticleFrontiers in cell and developmental biology2020
Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells Alleviate Dextran Sulfate Sodium-Induced Colitis by Increasing Regulatory T Cells in Mice.
Article in Frontiers in cell and developmental biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05784519 (Clinical Study of Mesenchymal Stem Cell Eye Drops for Treating Dry Eye Disease), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Study of Mesenchymal Stem Cell Eye Drops for Treating Dry Eye Disease
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Stem cell therapy for Crohn's disease: systematic review and meta-analysis of preclinical and clinical studies.Stem cell research & therapy · 2021Pooled it
- Stem Cell Therapy for Inflammatory Diseases: Progress, Challenges, and Future Directions.MedComm · 2026Review
- Therapeutic evaluation of iPSC-derived CD146+ mesenchymal stem cells in ulcerative colitis: biological properties and potential mechanisms.Stem cell research & therapy · 2025Article
- Camellia nitidissima Chi extract ameliorates dextran sulfate sodium-induced acute ulcerative colitis in mice by inhibiting TLR4/NF-κB-mediated inflammatory activation.Inflammopharmacology · 2025Article
- Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Autoimmune Diseases.Clinical reviews in allergy & immunology · 2025Review
- Therapeutic role of extracellular vesicles from human umbilical cord mesenchymal stem cells and their wide therapeutic implications in inflammatory bowel disease and other inflammatory disorder.Frontiers in medicine · 2024Review
- Nestin+ Peyer's patch resident MSCs enhance healing of inflammatory bowel disease through IL-22-mediated intestinal epithelial repair.Cell proliferation · 2023Article
- Therapeutic potential of mesenchymal stem/stromal cells (MSCs)-based cell therapy for inflammatory bowel diseases (IBD) therapy.European journal of medical research · 2023Review
- Stem Cell Therapy in Inflammatory Bowel Disease: A Review of Achievements and Challenges.Journal of inflammation research · 2023Review
- Mesenchymal stem cell-derived extracellular vesicles for cell-free therapy of ocular diseases.Extracellular vesicles and circulating nucleic acids · 2022Review
- Exosomes as a New Delivery Vehicle in Inflammatory Bowel Disease.Pharmaceutics · 2021Review
- Intestinal Macrophage Autophagy and its Pharmacological Application in Inflammatory Bowel Disease.Frontiers in pharmacology · 2021Review
- Regulatory Effect of Mesenchymal Stem Cells on T Cell Phenotypes in Autoimmune Diseases.Stem cells international · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD), which main clinical manifestations include abdominal pain and diarrhea occurring repeatedly, is a kind of autoimmune disease. It has been reported in preceding studies that mesenchymal stem cells (MSCs) can reduce inflammation by regulating the function of immune cells. But studies about the interaction between MSCs and adaptive immune cells, especially in IBD models, are insufficient. Therefore, the objective of this research was to estimate the therapeutic effects of MSCs from human umbilical cord blood (hUCB-MSCs) in an IBD model of rodent and to clarify the therapeutic mechanisms of hUCB-MSCs. Dextran sulfate sodium (DSS) was used to induce colitis in rodent. Mice with colitis were treated with intraperitoneal infusions of hUCB-MSCs and evaluated for mortality and diverse disease symptoms containing weight reduction, diarrhea, and bloody stools. The levels of histopathologic severity and generation of regulatory T cells (Treg) were also determined. Treatment with hUCB-MSCs ameliorated the clinical and histopathologic severity of acute and chronic colitis in mice. Furthermore, T cell infiltration into the inflamed colon was significantly decreased (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.